CN113272304B - Akt抑制剂 - Google Patents
Akt抑制剂 Download PDFInfo
- Publication number
- CN113272304B CN113272304B CN202080005749.9A CN202080005749A CN113272304B CN 113272304 B CN113272304 B CN 113272304B CN 202080005749 A CN202080005749 A CN 202080005749A CN 113272304 B CN113272304 B CN 113272304B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- methyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410142331.2A CN117964620A (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019100848013 | 2019-01-29 | ||
| CN201910084801 | 2019-01-29 | ||
| PCT/CN2020/073798 WO2020156437A1 (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410142331.2A Division CN117964620A (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113272304A CN113272304A (zh) | 2021-08-17 |
| CN113272304B true CN113272304B (zh) | 2024-03-29 |
Family
ID=71841634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080005749.9A Active CN113272304B (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
| CN202410142331.2A Pending CN117964620A (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410142331.2A Pending CN117964620A (zh) | 2019-01-29 | 2020-01-22 | Akt抑制剂 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12617784B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3919491B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7617005B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102892239B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN113272304B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020214258B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3127884A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3037595T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3919491T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020156437A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023520140A (ja) * | 2020-03-17 | 2023-05-16 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合二環系誘導体、その調製方法及びその医薬的応用 |
| CN115485276B (zh) * | 2020-05-15 | 2024-05-31 | 南京正大天晴制药有限公司 | 氘代akt激酶抑制剂 |
| US12673061B2 (en) | 2020-07-22 | 2026-07-07 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Unit dosage composition of AKT inhibitor |
| EP4186902A4 (en) * | 2020-07-22 | 2024-06-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | DIHYDROPYRIDO[2,3-D]PYRIMIDINONE DERIVATIVE SALT, PREPARATION METHOD AND USE THEREOF |
| JP7472391B2 (ja) * | 2020-07-22 | 2024-04-22 | 南京正大天晴制薬有限公司 | ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩及び結晶形 |
| CN116478156A (zh) * | 2022-01-17 | 2023-07-25 | 南京正大天晴制药有限公司 | 一种akt抑制剂化合物的富马酸盐晶型及其制备方法 |
| WO2024146599A1 (zh) * | 2023-01-06 | 2024-07-11 | 南京正大天晴制药有限公司 | 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途 |
| CN121586576A (zh) | 2023-06-14 | 2026-02-27 | 南京正大天晴制药有限公司 | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 |
| CN120157686A (zh) * | 2023-12-14 | 2025-06-17 | 南京正大天晴制药有限公司 | 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用 |
| CN121177294B (zh) * | 2025-11-27 | 2026-02-27 | 四川省医学科学院·四川省人民医院 | Akt抑制剂在制备诱导胰岛移植免疫耐受药物中的应用 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882347A (zh) * | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
| WO2009089462A1 (en) * | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| CN101578273A (zh) * | 2006-07-06 | 2009-11-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶 |
| CN105051043A (zh) * | 2012-11-16 | 2015-11-11 | 默克专利有限公司 | 用作激酶活性调节剂的新颖的杂环类衍生物 |
| CN109020957A (zh) * | 2017-06-12 | 2018-12-18 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2481336C2 (ru) * | 2006-07-06 | 2013-05-10 | Эррэй Биофарма Инк. | Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт |
| DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
| US20130065908A1 (en) * | 2009-12-07 | 2013-03-14 | Array Biopharma Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
| BR112012011328A2 (pt) * | 2009-10-23 | 2016-11-22 | Lilly Co Eli | inibidores de akt |
| AR093511A1 (es) * | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas |
| EP3189036B1 (en) * | 2014-09-05 | 2023-07-19 | ArQule, Inc. | Compositions and methods for treating proliferation disorders |
| CN108503645A (zh) * | 2018-03-01 | 2018-09-07 | 山东大学 | 含氨甲基的哌嗪酮类化合物及其制备方法和应用 |
| EP3784669B1 (en) * | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
-
2020
- 2020-01-22 US US17/426,047 patent/US12617784B2/en active Active
- 2020-01-22 WO PCT/CN2020/073798 patent/WO2020156437A1/zh not_active Ceased
- 2020-01-22 CN CN202080005749.9A patent/CN113272304B/zh active Active
- 2020-01-22 ES ES20748221T patent/ES3037595T3/es active Active
- 2020-01-22 AU AU2020214258A patent/AU2020214258B2/en active Active
- 2020-01-22 CA CA3127884A patent/CA3127884A1/en active Pending
- 2020-01-22 PL PL20748221.7T patent/PL3919491T3/pl unknown
- 2020-01-22 CN CN202410142331.2A patent/CN117964620A/zh active Pending
- 2020-01-22 KR KR1020217027161A patent/KR102892239B1/ko active Active
- 2020-01-22 JP JP2021543533A patent/JP7617005B2/ja active Active
- 2020-01-22 EP EP20748221.7A patent/EP3919491B1/en active Active
-
2024
- 2024-09-19 JP JP2024161770A patent/JP2024175091A/ja not_active Withdrawn
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882347A (zh) * | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
| CN101578273A (zh) * | 2006-07-06 | 2009-11-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶 |
| WO2009089462A1 (en) * | 2008-01-09 | 2009-07-16 | Array Biopharma Inc. | 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors |
| CN105051043A (zh) * | 2012-11-16 | 2015-11-11 | 默克专利有限公司 | 用作激酶活性调节剂的新颖的杂环类衍生物 |
| CN109020957A (zh) * | 2017-06-12 | 2018-12-18 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102892239B1 (ko) | 2025-11-26 |
| JP2022517866A (ja) | 2022-03-10 |
| CN117964620A (zh) | 2024-05-03 |
| KR20210120054A (ko) | 2021-10-06 |
| EP3919491A4 (en) | 2022-10-19 |
| AU2020214258B2 (en) | 2025-08-28 |
| PL3919491T3 (pl) | 2025-10-20 |
| US12617784B2 (en) | 2026-05-05 |
| EP3919491B1 (en) | 2025-05-28 |
| US20220144821A1 (en) | 2022-05-12 |
| EP3919491C0 (en) | 2025-05-28 |
| CA3127884A1 (en) | 2020-08-06 |
| AU2020214258A1 (en) | 2021-09-16 |
| ES3037595T3 (en) | 2025-10-03 |
| WO2020156437A1 (zh) | 2020-08-06 |
| JP7617005B2 (ja) | 2025-01-17 |
| EP3919491A1 (en) | 2021-12-08 |
| CN113272304A (zh) | 2021-08-17 |
| JP2024175091A (ja) | 2024-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7617005B2 (ja) | Akt阻害剤 | |
| AU2020337938B2 (en) | KRas G12D inhibitors | |
| TWI841200B (zh) | 雜環類化合物、藥物組成物及其應用 | |
| CN111153901B (zh) | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 | |
| CA3217830A1 (en) | 2-aminobenzothiazole compounds and methods of use thereof | |
| TW202417455A (zh) | 新穎三雜環化合物及藥學組成物 | |
| ES2871524T3 (es) | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas | |
| CA3198885A1 (en) | Azaquinazoline pan-kras inhibitors | |
| WO2016007185A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| WO2011152485A1 (ja) | 新規4,5-縮環ピリミジン誘導体 | |
| CN115916350B (zh) | Akt抑制剂的单位剂量组合物 | |
| CN115485276B (zh) | 氘代akt激酶抑制剂 | |
| US20250320213A1 (en) | Nitrogen-Containing Heterocyclic Compounds | |
| HK40050826A (en) | Akt inhibitor | |
| HK40050826B (en) | Akt inhibitor | |
| AU2021326929A9 (en) | Aromatic ring-lactam compound, preparation method therefor and use thereof | |
| WO2024086939A1 (en) | Purine compounds, compositions comprising them and uses thereof | |
| EP4727945A1 (en) | 3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca2 degrading protacs for the treatment of cancer | |
| EA053265B1 (ru) | Тетрагетероциклическое соединение | |
| HK40029944A (en) | Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use | |
| HK40029944B (en) | Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40050826 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |